H2020Индивидуална стипендия2017–2018

MONONANOCHEM · In vivo engineering of monocytes loaded with nano-chemotherapeutic formulations: a novel live-cell mediated drug delivery system for the treatment of cancer

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2017-01-01 → 2018-12-31
Финансиране от ЕС: 168 277 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Моноцитите се използват като транспортни средства за доставка на наночастици с химиотерапевтични лекарства (като доксорубицин) директно в туморните тъкани. Този метод помага за по-ефективното проникване на лекарствата през сложната среда на раковите клетки.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

In vivo engineering of monocytes loaded with nano-chemotherapeutic formulations: a novel live-cell mediated drug delivery system for the treatment of cancer

The success of current anti-tumoral therapies largely depends on the availability of appropriate drug delivery strategies, which have to allow the penetration of these drugs through the tumoral microenvironment. The knowledge related to the cellular heterogeneity of the tumors has advanced enormously in the last years. The recent studies showed that tumor associated macrophages (TAMs) can represent up to 50% of the tumor mass. TAMs are derived from circulating monocytes, which are recruited from the peripheral blood towards the tumor in response to a broad range of molecular signals. Recently several studies are focused on the development of therapeutic strategies targeting TAMs, however, the possibility to use monocytes, with excellent ability to infiltrate the abnormal tumoral tissue, to deliver chemotherapeutic drugs into the tumor has been hardly explored. Here, we aim to use the host monocytes, with high ability to infiltrate the tumoral tissues, to deliver chemotherapeutic nanoformulations into the bulk of the tumor. We have developed Nano-Formulations consisting in Poly(Lactide-co-Glycolide) (PLGA) nanostructures, allowing the loading of chemotherapeutic drugs into monocytes. Cytotoxic drugs inducing immunogenic cell death (Doxorubicin), and thus the recruitment of new monocytes, were used to enhance the efficacy of the therapy. Overall, we used Monocytes loaded with ChemoTherapeutic Nano-Formulations (MCTNFs) as a new strategy to deliver cytotoxic drugs towards the tumoral cells, taking advantage of the infiltration ability of the monocytes into tumor microenvironment. The MCTNFs were tested using appropriate in vitro 2D tumor models and in vivo murine tumor models. We expect that this new live-cell mediated drug delivery system will provide greater progress in the treatment of cancer.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The success of current antitumoural therapies largely depends on the availability of appropriate drug delivery strategies, which have to allow the penetration of these drugs through the tumoural microenvironment. The knowledge related to the cellular heterogeneity of the tumours has advanced enormously in the last years. Tumour associated macrophages (TAM) can represent up to 50% of the tumour mass. TAM are derived from circulating monocytes, which are recruited from the peripheral blood towards the tumour in response to a broad range of molecular signals (i.e. cytokines). Recently several studies are focused on the development of therapeutic strategies targeting TAM, however, the possibility to use monocytes, with excellent ability to infiltrate the abnormal tumoural tissue, to deliver chemotherapeutic drugs into the tumour has been hardly explored.Here, we aim to use the host monocyte/macrophage cells, with high ability to infiltrate the tumoural tissues, to deliver nano-chemotherapeutic formulations into the bulk of the tumour. We will develop Nano-Formulations consisting in Hyaluronic Acid (HA) nanostructures decorated with beta-glucans, allowing the targeting of specific receptors on the host circulating monocytes (Dectin-1), and at the same time, the loading of chemotherapeutic drugs into these cells. Cytotoxic drugs inducing immunogenic cell death (i.e. bortezomib), and thus the recruitment of new monocytes, will be used to enhance the efficacy of the therapy. Overall, we will use Monocytes loaded with Nano-ChemoTherapeutic Formulations (MNCTFs) as a new strategy to deliver cytotoxic drugs towards the tumoural cells, taking advantage of the infiltration ability of the monocytes/macrophages into tumour microenvironment. The MNCTFs will be tested using appropriate in vitro 2D and 3D tumour models and in vivo murine tumour models. We expect that this new live-cell mediated drug delivery system will provide greater progress in the treatment of cancer.

Оригинален текст от CORDIS (на английски).

Участници

HUMANITAS MIRASOLE SPA · Rozzano (Mi)КоординаторИталия